Investigation of the in vitro activity of tigecycline against Burkholderia pseudomallei and Burkholderia thailandensis revealed that the inhibition zone diameters of tigecycline against all isolates were >20 mm and that the MIC 50 values were 0.5 and 1 g/ml and the MIC 90 values were 2 and 1.5 g /ml for B. pseudomallei and B.  thailandensis, respectively. 
assimilation test (20) . In vitro susceptibilities were determined by Kirby-Bauer disk diffusion, Etest, and MicroScan. Paper disks containing tigecycline at 15 g per disk (Becton Dickinson), Etest strips (AB Biodisk), and gram-negative MicroScan MIC panels (Dade Behring Inc.) were provided by Wyeth Research. Susceptibility testing was done by direct colony suspension according to guidelines suggested by CLSI (4) . Quality control was performed by testing the susceptibility of Escherichia coli ATCC 25922 as recommended by Wyeth Research.
The distribution of inhibition zone diameters of tigecycline against B. pseudomallei and B. thailandensis is shown in Table 1 . All strains had an inhibition zone diameter of Ն20 mm. The MIC 50 and MIC 90 values of tigecycline as determined by Etest are shown in Table 2 . The MIC 50 values were 0.5 and 1 g/ml for B. pseudomallei and B. thailandensis, respectively. The MIC 90 values were 2 and 1.5 g/ml for B. pseudomallei and B. thailandensis, respectively. There was a significant correlation between inhibition zone diameters and MICs from Etest (P Ͻ 0.001; r ϭ Ϫ0.68). The mean inhibition zone diameters of the strains with MIC of 3, 2, 1.5, 1. 0.75, and 0.5 g/ml were 20, 21.8, 22.6, 23.5. 24.4, and 26.7 mm, respectively. The correlation of MICs determined by Etest and MicroScan was satisfactory, as shown in Table 3 . Thirty-two strains (50%) had identical MICs determined by Etest and MicroScan, whereas another 50% had a difference in MICs of 0.25 to 0.5 g/ml.
The MICs of tigecycline for B. pseudomallei and B. thailandensis observed in our study were higher than those for S. pneumoniae, Staphylococcus aureus, Enterococcus spp., and non-ESBL-producing Enterobacteriaceae (1). However, they were comparable to the MICs of tigecycline for Acinetobacter spp., Enterobacter aerogenes, and ESBL-producing Klebsiella pneumoniae (1) . The breakpoints for inhibition zone diameter and MIC of tigecycline against B. pseudomallei and B. thailandensis are not available. The breakpoint of doxycycline against B. pseudomallei, adapted from data compiled by the National Committee for Clinical Laboratory Standards for similar organisms to be used for susceptibility testing, was 4 g/ml (15) . The U.S. FDA-approved breakpoints of tigecycline against Enterobacteriaceae to be used by local laboratories were an inhibition zone diameter of Ն19 mm and a MIC of Յ2 g/ml (4) . With the aforementioned breakpoints used to determine susceptibility of Burkholderia spp. to tigecycline, all isolates of B. pseudomallei and B. thailandensis were susceptible to tige-cycline according to the inhibition zone diameter criteria and 98% of B. pseudomallei isolates and all B. thailandensis isolates were susceptible to tigecycline according to the MIC criteria. The MICs determined by Etest were significantly correlated with the inhibition zone diameters and the MICs determined by MicroScan. Therefore, disk diffusion and Etest methods are reliable for determination of susceptibility of tigecycline against B. pseudomallei and B. thailandensis.
Pharmacokinetic and pharmacodynamic studies of tigecycline in healthy subjects after a 100-mg loading dose given intravenously followed by 50 mg every 12 h have been reported (5, (12) (13) (14) 18) . The mean maximum concentration (C max ), the mean time to maximum concentration, the mean minimum concentration (C min ), the mean area under the curve, and the mean half-life of tigecycline in serum were 0.72 g/ml, 0.52 h, 0.1 g/ml, 1.73 g · h/ml, and 15 h, respectively. These profiles were favorable for many organisms, such as S. pneumoniae, Chlamydia pneumoniae, Moraxella catarrhalis, Mycoplasma pneumoniae, and Haemophilus influenzae, since the MIC 90 values of tigecycline for such organisms were very low. The mean C max of tigecycline in serum (0.72 g/ml) after the conventional dose of tigecycline (100-mg loading dose followed by 50 mg every 12 h) was above the MICs of tigecycline for only 6% of B. pseudomallei and B. thailandensis isolates. However, it was found that tigecycline had a large volume of distribution (7 to 10 liters/kg), indicating extensive distribution into the tissues (13) . In addition, the mean C max , the mean time to maximum concentration, the mean C min , the mean area under the curve, and the mean half-life of tigecycline in the alveolar cells were 15.2 g/ml, 2 h, 6.4 g/ml, 134 g · h/ml, and 23.7 h, respectively (5) . These observations imply that tigecycline accumulates in the cells and could be effective for infections caused by intracellular organisms. The mean C max and the mean C min of tigecycline in the alveolar cells were much higher than the MICs for all isolates of B. pseudomallei and B. thailandensis. Therefore, tigecycline should be a suitable antibiotic for therapy of melioidosis, since B. pseudomallei is an intracellular bacterium (9, 10, 16) . This hypothesis needs further investigation by conducting clinical trials on therapy of melioidosis with tigecycline.
We thank Wyeth Research for providing tigecycline susceptibility disks, Etest strips, and gram-negative MicroScan tests.
We thank the Thailand Research Fund for supporting the study. 
